Overview
Protozoal esophagitis, while less commonly discussed compared to other protozoal infections like those affecting the central nervous system, represents a significant yet under-recognized condition in veterinary medicine, particularly in horses and livestock. The primary protozoa implicated include Sarcocystis spp., Neospora spp., and Toxoplasma gondii. These parasites can cause a range of clinical presentations, from subtle to severe, depending on the host species and the specific protozoal strain involved. Understanding the epidemiology, clinical presentation, diagnosis, differential diagnosis, management, and prognosis of protozoal esophagitis is crucial for effective clinical intervention and patient care. This guideline synthesizes current evidence to provide clinicians with a comprehensive framework for addressing these infections.
Epidemiology
The epidemiology of protozoal infections varies significantly across different host species and geographic regions. In horses, Neospora caninum and Sarcocystis spp. are notable pathogens, with seroprevalence studies offering critical insights into regional risks. For instance, a study conducted in Alberta, Canada, reported an 81.8% seroprevalence of antibodies against Neospora caninum and 85.1% against Sarcocystis spp. in healthy horses, highlighting the widespread exposure to these pathogens in equine populations [PMID:41934607]. This high seroprevalence underscores the potential for endemic transmission within equine communities, necessitating vigilant surveillance and preventive measures.
In livestock, particularly goats, the seroprevalence data further illustrate the broad impact of protozoal infections. A study from Argentina found that Saanen breed goats exhibited seroprevalences of 81.8% for Neospora caninum, 85.1% for Sarcocystis spp., and 66.7% for Toxoplasma gondii, indicating a significant burden of these infections in goat herds [PMID:40915597]. Such high seroprevalence rates suggest that protozoal infections are not isolated incidents but rather persistent threats within these populations, potentially affecting productivity and health outcomes. Additionally, an epizootic outbreak of equine protozoal myeloencephalitis (EPM) affecting 12 out of 21 horses on a Kentucky farm over a six-month period highlights the potential for localized outbreaks, emphasizing the need for targeted epidemiological studies to identify risk factors and control strategies [PMID:9096721].
Clinical Presentation
The clinical presentation of protozoal esophagitis can be insidious, often beginning with subtle signs that may be easily overlooked. In horses, initial symptoms may include mild weight loss, decreased appetite, and vague gastrointestinal discomfort, which can progress to more pronounced neurologic manifestations if left undetected. A notable study on EPM in horses demonstrated that clinical signs initially appeared subtle but eventually evolved into significant neurologic deficits, including ataxia, muscle atrophy, and behavioral changes [PMID:9096721]. Early detection and continuous monitoring are crucial to mitigate the progression to severe neurologic impairment, underscoring the importance of thorough clinical evaluations and periodic reassessment in affected animals.
In other species, such as goats, protozoal infections like those caused by Toxoplasma gondii can manifest differently, often impacting productivity rather than overt clinical signs. Higher titers of antibodies to Toxoplasma gondii were associated with reduced milk production in goats, indicating subclinical infections with economic implications [PMID:40915597]. Thus, clinicians should consider both overt clinical symptoms and subtle changes in performance metrics when evaluating animals suspected of protozoal esophagitis.
Diagnosis
Diagnosing protozoal esophagitis requires a multifaceted approach, leveraging serological tests and cerebrospinal fluid (CSF) analysis where applicable. Serological methods, including Indirect Fluorescent Antibody Test (IFAT) and Enzyme-Linked Immunosorbent Assay (ELISA), play pivotal roles in detecting antibodies against specific protozoal pathogens. For instance, a study utilizing IFAT and ELISA effectively identified antibodies against Sarcocystis neurona and Neospora hughesi in equine populations, underscoring their utility in surveillance and diagnosis [PMID:41934607]. However, the diagnostic landscape is complicated by potential cross-reactivity and species-specific antigenic similarities. Experimental studies in Mongolian gerbils revealed that while IFAT did not show cross-reactivity between Sarcocystis neurona and Sarcocystis falcatula-like, Western blot (WB) analysis indicated overlapping antigenic patterns, particularly for proteins of 30 and 16 kDa [PMID:31704559]. This suggests that WB might yield false positives in clinical settings, necessitating careful interpretation and potentially the integration of multiple diagnostic modalities to confirm infection accurately.
In horses diagnosed with EPM, the presence of neurologic signs coupled with positive CSF antibodies to Sarcocystis neurona provided definitive diagnostic support [PMID:9096721]. Clinicians should therefore consider a combination of clinical signs, serological evidence, and CSF analysis when diagnosing protozoal esophagitis, ensuring a comprehensive approach to confirmatory testing.
Differential Diagnosis
Differentiating protozoal esophagitis from other gastrointestinal and neurologic conditions is essential for accurate diagnosis and appropriate management. In goats, elevated IFAT titers to Toxoplasma gondii have been linked to reduced milk production, suggesting that subclinical protozoal infections can impact productivity without overt clinical signs [PMID:40915597]. This highlights the importance of considering protozoal infections in animals presenting with unexplained declines in performance metrics.
Diagnostic specificity remains a challenge, particularly when distinguishing between closely related protozoa like Sarcocystis spp. IFAT has been noted to be more specific compared to WB in detecting antibodies to S. falcatula-like and S. neurona, indicating that while WB can provide detailed antigenic information, IFAT may offer greater reliability in clinical settings [PMID:31704559]. Clinicians must be vigilant in employing these diagnostic tools judiciously, considering the potential for cross-reactivity and species-specific nuances. Other differential diagnoses might include parasitic infections (e.g., strongylid nematodes), inflammatory bowel diseases, and idiopathic neurologic disorders, necessitating a thorough clinical history, physical examination, and targeted diagnostic testing to rule out these alternatives effectively.
Management
The management of protozoal esophagitis primarily revolves around antimicrobial therapy, though the choice and duration of treatment must be carefully considered due to potential adverse effects. Treatment regimens often include the use of pyrimethamine and trimethoprim-sulfamethoxazole, which have shown efficacy against protozoal infections such as those caused by Sarcocystis neurona. However, these treatments are not without risks; adverse effects observed in horses include transient fever, anorexia, depression, worsening of ataxia, mild anemia, and in severe cases, abortions [PMID:9096721]. Therefore, close monitoring of treated animals is essential to manage these side effects promptly.
Supportive care is also critical, encompassing nutritional support, symptomatic treatment of neurologic symptoms, and ensuring a stress-free environment to facilitate recovery. In cases where neurologic deficits persist, extended treatment durations may be necessary, with treatment periods ranging from 45 to 211 days, depending on the response and persistence of CSF antibodies [PMID:9096721]. Tailoring the treatment plan to individual patient needs, guided by clinical response and diagnostic reassessment, is paramount for optimizing outcomes.
Prognosis & Follow-up
The prognosis for animals with protozoal esophagitis varies widely based on the severity of clinical signs, the specific protozoal agent involved, and the timeliness and efficacy of treatment. Horses with EPM often require prolonged treatment courses, with some individuals needing extended therapy due to persistent CSF antibodies, indicating a need for vigilant follow-up [PMID:9096721]. Regular monitoring through clinical evaluations, repeat serological testing, and periodic CSF analysis can help assess treatment efficacy and detect any relapse early.
Long-term follow-up is crucial to evaluate the resolution of clinical signs and to manage any residual neurologic deficits. Clinicians should maintain a watchful eye on the animal's overall health, performance metrics, and quality of life post-treatment. While some cases may show significant improvement and return to normal function, others might require ongoing supportive care to manage chronic symptoms. Continuous reassessment and adaptive management strategies are key to ensuring the best possible outcome for affected animals.
Key Recommendations
These recommendations aim to guide clinicians in effectively managing protozoal esophagitis, ensuring optimal patient outcomes through a multifaceted and evidence-based approach.
References
1 Sjolin E, Zakia LS, Galezowski A, Whitehead AE. Seroprevalence of Sarcocystis neurona and Neospora hughesi in healthy horses from the province of Alberta, Canada. Journal of veterinary internal medicine 2026. link 2 Steffen KD, Gortari Castillo L, Gos ML, Venturini MC, Arias RO, Moré G. Neospora caninum, Sarcocystis spp. and Toxoplasma gondii infections and their relationship with milk production in goats from Argentina. Parasitology international 2026. link 3 de Jesus RF, Borges-Silva W, Bezerra TL, Gondim LQ, Uzêda RS, Gondim LFP. Serologic cross-reactivity between Sarcocystis neurona and Sarcocystis falcatula-like in experimentally infected Mongolian gerbils. Veterinary parasitology 2019. link 4 Fenger CK, Granstrom DE, Langemeier JL, Stamper S. Epizootic of equine protozoal myeloencephalitis on a farm. Journal of the American Veterinary Medical Association 1997. link
4 papers cited of 6 indexed.